<DOC>
	<DOCNO>NCT00101894</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability AMG 706 plus panitumumab administer either FOLFIRI FOLFOX4 chemotherapy regimens . This Phase 1b clinical study .</brief_summary>
	<brief_title>Safety AMG 706 Plus Panitumumab Plus Chemotherapy Treatment Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>For complete inclusion exclusion criterion , please refer investigator . Inclusion Criteria 1 . Competent comprehend , sign , date Institutional Review Board ( IRB ) approve informed consent form 2 . Diagnosis metastatic colorectal adenocarcinoma ( may receive 1 prior chemotherapy regimen metastatic CRC ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 4 . Adequate hematological function 5 . Adequate renal function 6 . Adequate hepatic function 7 . Life expectancy great equal 3 month document investigator 1 . More 1 prior chemotherapy regimen metastatic CRC 2 . Central nervous system ( CNS ) metastases 3 . History venous thrombosis 4 . Myocardial infarction , cerebrovascular accident , transient ischemic attack , grade 2 great peripheral vascular disease , congestive heart failure , ongoing arrhythmias require medication , unstable angina within 1 year study enrollment 5 . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis screen chest compute tomograph ( CT ) scan 6 . Average systolic blood pressure &gt; 150mm Hg average diastolic blood pressure &gt; 90mm Hg 7 . Radiotherapy within 28 day study enrollment within 14 day study enrollment peripheral lesion 8 . Prior AMG 706 , oral inhibitor AMG706 , panitumumab , another antiEGFr monoclonal antibody ( mAb ) ( e.g. , cetuximab [ ErbituxÂ® ] EMD 72000 ) 9 . Systemic chemotherapy within 28 day study enrollment 10 . Major surgery within 28 day minor surgery within 7days study enrollment 11 . History life threaten ventricular arrhythmia ( eg , sustain ventricular tachycardia ) 12 . Female male subject childbearing potential use adequate contraceptive precaution 13 . Participation therapeutic clinical trial within 30 day study enrollment 14 . Not recover previous therapy 15 . Clinically significant open would , ulcer fracture 16 . Any comorbid medical condition would increase risk toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>AMG 706</keyword>
	<keyword>Panitumumab</keyword>
</DOC>